Interleukin-27: biological properties and clinical application

Arch Immunol Ther Exp (Warsz). 2010 Dec;58(6):417-25. doi: 10.1007/s00005-010-0098-6. Epub 2010 Sep 26.

Abstract

Interleukin (IL)-27 is a novel cytokine secreted by stimulated antigen-presenting cells. Initial studies on the biology of IL-27 provided evidence for its role in the initiation of T(H)1 responses; however, subsequent work has indicated that IL-27 has broad inhibitory effects on T(H)1, T(H)2, and T(H)17 subsets of T cells as well as the expansion of inducible regulatory T cells. The involvement of IL-27 in the regulation of angiogenesis and antiviral response has also recently been reported. The aim of this review is to highlight the potential areas of IL-27 clinical application, especially the management of neoplastic and viral diseases as well as autoimmune disorders, including rheumatoid arthritis and multiple sclerosis. The review will also serve to elaborate on the molecular mechanisms involved in the expression of this cytokine and signaling from the IL-27 receptor.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Antiviral Agents / therapeutic use
  • Autoimmune Diseases / immunology
  • Autoimmune Diseases / therapy
  • Gene Expression Regulation
  • Humans
  • Immunity, Cellular
  • Inflammation / immunology
  • Inflammation / prevention & control
  • Interleukins / genetics
  • Interleukins / metabolism*
  • Interleukins / therapeutic use
  • Neoplasms / immunology
  • Neoplasms / therapy
  • Receptors, Interleukin / metabolism*
  • Signal Transduction*
  • T-Lymphocytes, Regulatory / immunology
  • Th1 Cells / immunology
  • Th2 Cells / immunology
  • Virus Diseases / immunology
  • Virus Diseases / therapy

Substances

  • Anti-Inflammatory Agents
  • Antineoplastic Agents
  • Antiviral Agents
  • Interleukins
  • MYDGF protein, human
  • Receptors, Interleukin